Kidney disease biotech Chinook Therapeutics has set up a joint venture called SanReno Therapeutics with an investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners Chinam, and more news from BeyondSpring, Everest, Zai Lab and ITabMed.
Everest Medicines and AbCellera entered a multi-year collaboration to discover therapeutic antibodies for up to 10 targets selected by Everest. This is the third deal Everest disclosed in two weeks.
Everest will pay Suzhou Sinovent and SinoMab BioScience up to $561 million to license the global rights to BTK inhibitor XNW1011, four days after the mRNA transaction with Providence that is worth over $500 million.
